What is the role of pulmonary function testing in the diagnosis of diffuse parenchymal lung diseases (DPLDs)?

Updated: Sep 15, 2020
  • Author: Eleanor M Summerhill, MD, FACP, FCCP; Chief Editor: Zab Mosenifar, MD, FACP, FCCP  more...
  • Print
Answer

Pulmonary function testing may demonstrate reduced lung volumes with testing of total lung capacity, forced expiratory volume in 1 second, and forced vital capacity. The ratio of forced expiratory volume in 1 second to forced vital capacity is usually normal or increased. Diffusing capacity for carbon monoxide (DLCO) is generally reduced. Static pulmonary compliance is reduced. The restrictive defect may be absent in patients with significant smoking history due to coexistent chronic obstructive pulmonary disease. An obstructive defect may be present in patients with coexistent chronic obstructive pulmonary disease, sarcoidosis, LAM, and eosinophilic granuloma.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!